 - All patients will be questioned about prior exposure to antibody therapy including OKT3, rituximab, trastuzumab, and gemtuzumab without affect to eligibility. Patients with prior exposure will have a blood sample collected for human anti-mouse antibody HAMA. For patients with no prior antibody therapy exposure, no further action will be taken. 